Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Brady Sillman"'
Autor:
Farhana Islam, Srijanee Das, Md Ashaduzzaman, Brady Sillman, Pravin Yeapuri, Mohammad Ullah Nayan, David Oupický, Howard E. Gendelman, Bhavesh D. Kevadiya
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-17 (2024)
Abstract An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug’
Externí odkaz:
https://doaj.org/article/724d71a1580b4ef987734da42550c3e9
Autor:
Emma G. Foster, Brady Sillman, Yutong Liu, Micah Summerlin, Vikas Kumar, Balasrinivasa R. Sajja, Adam R. Cassidy, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The World Health Organization has recommended dolutegravir (DTG) as a preferred first-line treatment for treatment naive and experienced people living with human immunodeficiency virus type one (PLWHIV). Based on these recommendations 15 million PLWH
Externí odkaz:
https://doaj.org/article/ba6d4ed836814c72aee66959707f131a
Autor:
Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, Lubaba A. Zaman, Lalitkumar K. Vora, Brady Sillman, Howard E. Gendelman, Benson Edagwa
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 183 (2024)
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs
Externí odkaz:
https://doaj.org/article/801fbe43738b4fdabac519e7aedc77ff
Autor:
Suyash Deodhar, Brady Sillman, Aditya N. Bade, Sean N. Avedissian, Anthony T. Podany, JoEllyn M. McMillan, Nagsen Gautam, Brandon Hanson, Bhagya L. Dyavar Shetty, Adam Szlachetka, Morgan Johnston, Michellie Thurman, Daniel J. Munt, Alekha K. Dash, Milica Markovic, Arik Dahan, Yazen Alnouti, Alborz Yazdi, Bhavesh D. Kevadiya, Siddappa N. Byrareddy, Samuel M. Cohen, Benson Edagwa, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Here, using animal models, Deodhar et al. single parenteral dose of dolutegravir (DTG) prodrug nanocrystals sustains drug protein-adjusted 90% inhibitory concentration for up to a year, without injection site reactions or systemic toxicities.
Externí odkaz:
https://doaj.org/article/0e6c6ddce7834d67b915c46f752da67f
Autor:
Nagsen Gautam, JoEllyn M. McMillan, Devendra Kumar, Aditya N. Bade, Qiaoyu Pan, Tanmay A. Kulkarni, Wenkuan Li, Brady Sillman, Nathan A. Smith, Bhagya L. Dyavar Shetty, Adam Szlachetka, Benson J. Edagwa, Howard E. Gendelman, Yazen Alnouti
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic an
Externí odkaz:
https://doaj.org/article/2bfe8aa999a043d6aa5d494a5ae8099d
Autor:
Prasanta K. Dash, Rafal Kaminski, Ramona Bella, Hang Su, Saumi Mathews, Taha M. Ahooyi, Chen Chen, Pietro Mancuso, Rahsan Sariyer, Pasquale Ferrante, Martina Donadoni, Jake A. Robinson, Brady Sillman, Zhiyi Lin, James R. Hilaire, Mary Banoub, Monalisha Elango, Nagsen Gautam, R. Lee Mosley, Larisa Y. Poluektova, JoEllyn McMillan, Aditya N. Bade, Santhi Gorantla, Ilker K. Sariyer, Tricia H. Burdo, Won-Bin Young, Shohreh Amini, Jennifer Gordon, Jeffrey M. Jacobson, Benson Edagwa, Kamel Khalili, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-20 (2019)
Here, the authors show that sequential treatment with long-acting slow-effective release ART and AAV9- based delivery of CRISPR-Cas9 results in undetectable levels of virus and integrated DNA in a subset of humanized HIV-1 infected mice. This proof-o
Externí odkaz:
https://doaj.org/article/ad4b010214414d8c84777d8ae90f684b
Autor:
Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable a
Externí odkaz:
https://doaj.org/article/9fe938444e464eaea1e85845549ff241
Autor:
Prasanta K. Dash, Chen Chen, Rafal Kaminski, Hang Su, Pietro Mancuso, Brady Sillman, Chen Zhang, Shuren Liao, Sruthi Sravanam, Hong Liu, Emiko Waight, Lili Guo, Saumi Mathews, Rahsan Sariyer, R. Lee Mosley, Larisa Y. Poluektova, Maurizio Caocci, Shohreh Amini, Santhi Gorantla, Tricia H. Burdo, Benson Edagwa, Howard E. Gendelman, Kamel Khalili
Publikováno v:
Proceedings of the National Academy of Sciences. 120
Treatment of HIV-1 ADA -infected CD34+ NSG-humanized mice with long-acting ester prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was followed by dual CRISPR-Cas9 C-C chemokine receptor type five (CCR5) and HI
Publikováno v:
NeuroImmune Pharmacology and Therapeutics.
Autor:
Larisa Y. Poluektova, Howard E. Gendelman, Brady Sillman, Prasanta K. Dash, Hang Su, Saumi Mathews, Sruthi Sravanam, Edward Makarov, Emiko Waight, Santhi Gorantla
Publikováno v:
Journal of Neuroimmune Pharmacology. 16:796-805
Defining the latent human immunodeficiency virus type 1 (HIV-1) burden in the human brain during progressive infection is limited by sample access. Human hematopoietic stem cells (hu-HSCs)-reconstituted humanized mice provide an opportunity for this